Key learning points: The firstlearningpoint from this case is to take asystematic approach to the diagnosis of connective tissue diseases. With so many overlapping symptoms and signs, and indeed, so many overlapping diagnoses, it is imperative that one takes a thorough and comprehensive multi-system history and examination. We have also gained an awareness of hypo-or amyopathic myositis as rare phenotypes of dermatomyositis, which will allow us to improve diagnostic acumen if faced with patients with the characteristic rashes and little or no muscle weakness. This case has also prompted us to actively consider whether new symptoms in patients with dermatomyositis can be explained by the diagnosis or whether they necessitate a search for further explanation. This is an important consideration when dealing with any patients with a multi-system disease. Without an open mind and appropriate investigation, underlying or secondary diagnoses can easily be missed. The recurrent infections could have been attributed to the immunosuppressive therapy alone, or else considered to be an expected complication of severe and widespread of skin breakdown, but fortunately was recognised and investigated appropriately.
Introduction: Statins are frequently prescribed, following or in order to prevent cardiovascular events. They inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCoA), an enzyme involved in cholesterol synthesis. Up to 20% of patients experience myalgia which resolve after the drug is stopped. We highlight a more serious and potentially lifethreatening complication: statin-induced autoimmune necrotising myositis (SIANM). Recently SIANM has been differentiated from inflammatory polymyositis. Patients present with bilateral proximal muscle weakness, elevated creatinine kinase, a muscle biopsy with necrosis and a positive HMGCoA reductase antibody. The latter has been found to be a specific and sensitiveinvestigation forSIANM. Case description: Given the rarity of SIANM, no guidelines available recommend a best course of treatment, here we highlight 3 successfully treatedpatients. Case 1: 72-year-old man with hypercholesterolaemia, type 2 diabetes and hypertension presented with progressive proximal symmetrical weakness for 6 months. He started 20mg atorvastatin a year earlier and stopped this 2 months before admission. Examination revealed 4/5 muscle strength proximally in all 4 limbs and the patient struggled to stand from sitting. CK was elevated at 8223 IU/L . EMG confirmed a myopathic process and MRI thighs showed active inflammation. A muscle biopsy and HMGCoA antibodies confirmed SIANM and the patient commenced IV and then oral steroids. The patient deteriorated rapidly over the subsequent days with progressive weakness and dysphonia. He developed bilateral pneumonias and was admitted to ITU. Here we commenced the patient on IV immunoglobulin (IVIG) and rituximab. With this he improved significantly,withincreasing power and a nor-malisedCK. Case 2: 55-year-old old man with a background of previous MI in 2013 (after which he commenced atorvastatin), type 2 diabetes, hypercholesterolemia and hypertension presented with progressive bilateral proximal muscle weakness. Serum CK found to be 8413, his statin was stopped and the patient underwent extensive investigation. Once again investigations confirmed the diagnosis of SIANM. The patient commenced steroid treatment but despite initial improvement in his power, this soon plateaued as did his CK. He was commenced on IVIG and methotrexate and found significant benefit withthese treatments. Case 3: 60-year-old lady presented with a 5-month history of generalised aches and pains with difficulty standing from sitting. She had been on atorvastatin for many years but her symptoms did not improve despite having stopped this 5 months previously. Investigations confirmed a SIANM. The patient was commenced on steroids and methotrexate with good effect. Discussion: Patients presenting on statins with proximal symmetrical weakness and a raised CK should have HMGCOA antibodies checked as part of a myositis screen. Though statins should always be stopped, patients with SIANM can continue to deteriorate despite drug discontinuation and steroid treatment. Such patients should be considered for immunosuppression. The 3 cases described show positive response to a combination of methotrexate, IVIG and/or rituximab. This seems to mirror the growing clinical experience in other published case reports. Key learning points: Patients presenting on statins with proximal symmetrical weakness and a raised CK should have HMGCOA antibodies checkedas partof amyositis screen. Withdrawal of the statin and steroid treatment alone is often insufficient to successfully treat SIANM. Close monitoring of a patient's power and CK levels are required even after withdrawal of a statin and treatment with steroid as patients can continue todeteriorate. In such cases, additional treatment with methotrexate, IVIG and/ or rituximab appearsto have the best outcomes. Conflicts of interest: The authors have declared no conflicts of interest. Introduction: Idiopathic inflammatory myopathies (IIM) have long been diagnosed using a defined number of clinical criteria (Bohan and Peter). The emergence of new myositis specific antibodies (MSAs) and their relation to specific disease phenotypes may be useful in establishing a new clinical-serological diagnostic criteria for different disease presentations and thus help to determine management and prognosis. We present a case of dermatomyositis (DM) where limb subcutaneous oedema; a rare manifestation of the disease, and severe dysphagia were prominent clinicalfeaturesinadditionwith thepresence ofanti-smallubiquitin-likemodifier activating enzyme (SAE) antibodies. Case description: A 63-year-old Pakistani male presented with weight loss, anorexia, odynophagia, and a rash over his scalp, chest, face and flexor surfaces. Initial blood results revealed hypoalbuminaemia, CRP 7mg/L and ESR 37mm/h. A CT chest revealed an anterior mediastinum soft tissue mass suggestive of necrosis, with multiple ill-defined nodes throughout the lungs. An endoscopy revealed severe gastritis. Oropharyngeal examination revealed pooling of saliva and mucositis. Ceftriaxone was commenced for apresumed infectiveaetiology. Video fluoroscopy confirmed pharyngeal dysphagia with aspiration. Examination demonstrated a non-fatigable bulbar sounding dysarthria. There was no tongue wasting or fasciculations. Power was globally reduced, with marked proximalupper and lower limb weakness. Nerve conduction studies revealed normal sensation, and most motor nerves had normal conduction velocities with small nerve responses. Electromyography showed areas withdenervation. With no improvement in the patient's condition, anti-tuberculosis and anti-fungal therapy were commenced, with pulsed methylprednisolone for three days followed by 80mg daily to cover for an organizing pneumonia. Subsequent cultures were negative. Progressive weight loss with muscle wasting ensued and later, facial hyperpigmentation was noted in addition to the development of facial, lip and arms swelling. He was rheumatoid factor positive >500 iu/ml, with a raised IgE 2912 g/L and IgG 37.6 g/L. A CT-PET scan revealed intense uptake in the muscles posterior of the neck, tongue and masticators. An MRI scan of his arms revealed several abnormal signals around the shoulder girdle, long muscles of the back, and upper arm, which guided the site for muscle biopsy. This revealed highly abnormal skeletal muscle with frequent atrophic and necrotic fibres overrun by macrophages and T-cell rich inflammation. These findings in addition to serology reporting the presenceof anti-SAE antibodies confirmed the diagnosis. Pulsed methylprednisolone, immunoglobulin therapy, and azathioprine were initiated with reducing prednisolone dose. Discussion: This case of DM with a generalised rash, severe dysphagia and limb subcutaneous oedema were salient features in addition to the presence of anti-SAE antibodies. Anti-SAE has been shown to be present exclusively in DM patients where rash and severe dysphagia are common clinical findings. Our patient presented with severe dysphagia, which can be difficult to manage requiring enteral feeding. Video fluoroscopy was particularly useful in this case helping to stratify the severity of dysphagia and we would urge other clinicians to use this tool when investigating patients with suspected dermatomyositis to avoid potential complications of poor swallow including aspiration pneumonia. The additional imaging modality of PET-CT in our case confirmed the involvement of the muscles of mastication thus could prove a useful tool when investigating involvement of swallowing muscles inpatients with anti-SAE DM. Skin features are another common finding in the anti-SAE group and our patient had a heliotrophic rash and shawl sign, which responded poorly to treatment. We describe the additional feature of severe subcutaneous limb and facial oedema, a rare manifestation of the disease, described in only a few other cases. Limb subcutaneous oedema is thought to reflect underlying severe muscle disease, is difficult to treat, and often is unresponsive to conventional treatment. Our case, and several other cases with the presence of limb oedema as reported in a literature search, required treatment with intravenous immunoglobulin and glucocorticoids, in additionwith azathioprine and methotrexate. This is the first reported case to our knowledge of a patient with positive ANA, RF, anti-ccp, and anti-small ubiquitin-like modifier activating enzyme (anti-SAE) antibodies. Key learning points: The finding of anti-SAE in our case where severe dysphagia was present provides further weight to this antibody being a useful serological marker to identify this subgroup of DM patients. Identifying this antibody may be helpful in creating management strategies for these patients and determining disease progression and prognosis. The presence of limb and facial oedema may be an overlying feature of the anti-SAE group; however, previous cases of limb oedemahavenot identified this antibody as the SAE test was unavailable.The presence of severe dysphagia and subcutaneous oedema suggests the presence of anti-SAE lends itself to a clinical phenotype of DM that is particularly severe and requires multidisciplinary input.
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WHEN IS INFLAMMATORY MYOSITIS NOT INFLAMMATORY MYOSITIS?
Annmarie McShane 1 , Maria Wray 1 , James Burns 1 , Jerry Sin 1 , Patrick Glass 2 , Christopher Beirne 2 , Aoibhinn Clinton 3 , and Brian Herron 3 1 Rheumatology, Northern Health and Social Care Trust, Antrim, United Kingdom, 2 Radiology, Northern Health and Social Care Trust, Antrim, United Kingdom, and 3 Neuropathology, Belfast Health and Social Care Trust, Belfast, United Kingdom Introduction: A 52-year-old man presented with extensive bilateral inflammatory myositis of the quadriceps on a background of pyrexia of unknown origin (PUO). He had markedly elevated acute phase reactants but had a normal CK and did not develop muscle weakness. This was a transient phenomenon which resolved spontaneously over 10 weeks. There was not an infective process identified and he was not treated with glucocorticoids or other immunosuppressants. This case highlights the importance of careful consideration of steroid treatment in atypical presentations without a clear diagnosis and the value of multidisciplinary involvement in patient care. Case description: The patient presented with a 2-week history of acute onset bilateral thigh pain, stiffness and persistent fevers following an episode of alcohol intake although symptoms may have preceded this. Myalgia was a prominent feature however he maintained full power of the hip flexors and all other proximal and distal muscle groups. No skin changes, swallow orrespiratory symptoms. CK was normal at presentation and remained low. Acute phase reactants were elevated including CRP 405mg/L, ESR 110mm/hr. Platelets 1000x10 9 /L, WCC 17.7x10 9 /L. Urinalysis and renal function normal. ALT raised at 136U/L. AST normal, other liver parameters raised in keeping with acute phase response. No previous episodes, no preceding travel, infection, bites, illicit drugs or family history of muscle disorders. He was taking astatin which was discontinued. PUO work up including cultures, viral titres, echocardiogram and CT imaging did not identify a source. Empiric antibiotics were trialled without improvement. ANA, ANCA and myositis panels were negative. MRI of thighs reported extensive inflammatory myositis involving the quadriceps bilaterally with mild involvement of biceps femoris. There were no features of an infected collection or rhabdomyolysis. Muscle biopsy showed a lymphocytic myositis with neurogenic atrophy. Differential included idiopathic inflammatory myositis (IIM) spectrum with viral myositis felt less likely. Clinically he remained sore but improving and mobilising. Daily pyrexias persisted but he remained fully strong with a low normal CK and a downward trend in inflammatory markers. Investigations for occult malignancy including CTPET and bone marrow biopsy were negative. Steroid treatment was not instigated. A watchful waiting approach was taken and his symptoms and blood investigations gradually improved. He embarked on a physiotherapist guided exercise programme. Follow up MRI at 10 weeks showed complete resolution of the inflammatory features. Discussion: This is a case of an acute onset myositis with systemic inflammatory features which resolved spontaneously. Differential diagnoses including inherited, metabolic and toxic myopathies were considered and discounted. Although alcohol had been taken and he had been taking a statin prior to onset, the clinical picture, normal CK and biopsy findings did not support these as likely culprits. Extensive viral and serology infective tests were negativeand the exact cause was not identified. The clinical features strongly mimicked an idiopathic inflammatory myositis (IIM) however atypical features including normal CK and lack of objective weakness led to continued doubt of an autoimmune aetiology. Additionally there were no upper limb or neck flexor symptoms and no extra-muscular manifestations. Applying the ACR/EULAR 2017 criteria for IIM to this case the probability of this diagnosis is 5% although this does not take into account the radiological findings. With evidence of inflammatory myositis and a dramatic acute phase response including persistent pyrexia there was a strong temptation to begin steroid therapy. His case was discussed with radiology, pathology and neurology and ultimately the decision towithholdwas justified. In this case improvement would have occurred with steroid which would likely have led to an incorrect diagnosis of IIM and the patient would have been unnecessarily treated with prolonged high dose steroid and disease modifying drugs with the associated side effects and long term sequelae. Key learning points: This case highlights the importance of confirming a diagnosis prior to initiating steroid therapy particularly if there are atypical features. Glucocorticoids would undoubtedly have led to a clinical improvement however this would have given rise to a misdiagnosis and unnecessary long term immunosuppression. There were many positive test results for inflammation including blood, imaging and muscle tissue but ultimately the clinical examination findings, particularly the absence of weakness, were consistent and the basis of the rationale to withhold steroid treatment. As clinical improvement progressed with supportive management this decision was justified. This demonstrates the importance of patient centred care and the value of the clinical examination. This was an unusual case therefore input and advice was sought from colleagues in neurology, neuropathology, rheumatology and radiology. This was vital to clinical care decisions and emphasizes the importance of a multidisciplinary approach in complex cases. Despite extensive investigations no cause was identified for this transient inflammatory myositis. This highlights the unknown elements within this spectrum of disease and the need forongoing reporting of atypical cases. Introduction: Myositis can be infective, metabolic or immune-mediated. Idiopathic inflammatory myopathy, which is immune-mediated, tends to be subacute, with symmetrical symptoms, overlap clinical features and positive autoimmune serology. We present a case of acute onset lower limb seronegative inflammatory myopathy with a normal creatinine kinase (CK), a marked acute phase response that responded promptly to immunomodulatory therapy. Case description: A 68-year-old man presented with a 2-week history of lower limb pain with subjective weakness, on a background of well-controlled type 2 diabetes mellitus and hypertension. He was admitted with worsening symptoms of markedleft thigh pain, night sweats, and fevers. On admission, he had swinging pyrexia (above >39 C) while remaining haemodynamically stable. He had focal tenderness over the left anterolateral thigh, with a good range of movement, normal power and no signs of focal collection or cellulitis. There were no extra-muscular features to suggest systemic infection oroverlap connective tissue disease. Bloods showed C-reactive protein (CRP) 225, normal CK 212 and negative blood cultures. X-rays knee, femur and pelvis were normal. Magnetic resonanceimaging (MRI)onT2,fat-suppressedSTIRsequencesdemonstrated increased signal/oedema both thighs throughout the anterior muscle compartment and along the fascial plane, notably most severe in the left vastus lateralis. He was treated empirically for infective myositis. Despite 14 days of broad-spectrum antibiotics, he remained febrile with persistently elevated CRP. There was no focal collection, lymphadenopathy or occult malignancy on CT abdomen and pelvis. Trans-oesophageal echocardiogram showed no evidence of infective endocarditis but revealed incidentalmoderate aortic stenosis. i20 26 September 2019 POSTER PRESENTATIONS
